Autologous retransplantation for patients with recurrent multiple myeloma

Multiple Myeloma

(2017) Kenneth C. Anderson et al.   Journal of the National Comprehensive Cancer Network

Carfilzomib in multiple myeloma: gold, silver, or bronze?

(2012) D. E. Reece   BLOOD

Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

(2012) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

(2012) Philip L. McCarthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses

(2012) H. Ludwig et al.   ONCOLOGIST

Factors Influencing the Outcome of a Second Autologous Stem Cell Transplant (ASCT) in Relapsed Multiple Myeloma: A Study from the British Society of Blood and Marrow Transplantation Registry

(2011) Gordon Cook et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival

(2011) Victor H. Jimenez-Zepeda et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

(2011) K. Neben et al.   BLOOD

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

(2011) G. J. Morgan et al.   BLOOD

Durable remission with salvage second autotransplants in patients with multiple myeloma

(2011) Nina Shah et al.   CANCER

Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation

(2011) Cecilie Blimark et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation

(2011) Roland Fenk et al.   LEUKEMIA & LYMPHOMA

Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences

(2010) Bart Barlogie et al.   JOURNAL OF CLINICAL ONCOLOGY

Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma

(2009) Julianna Aleathea Burzynski et al.   LEUKEMIA & LYMPHOMA

Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma

(2009) Jean-Luc Harousseau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma

(2008) R L Olin et al.   BONE MARROW TRANSPLANTATION